Business
Institute of Oncology Ljubljana Leverages SOPHiA DDM™ Platform for Cancer Research
SOPHiA DDM™ deep-learning algorithm will help determine HRD status of tumors for Institute of Oncology Ljubljana researchers BOSTON and LAUSANNE, Switzerland,
About this update from Sophia Genetics Sa
[{"type":"text","content":"SOPHiA DDM™ deep-learning algorithm will help determine HRD status of tumors for Institute of Oncology Ljubljana researchers\nBOSTON and LAUSANNE, Switzerland, May 24, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the Institute of Oncology Ljubljana (IOL), a comprehensive public institution for detection, treatment and research of cancer, based in Ljubljana, Slovenia, is live on SOPHiA DDM™. To help advance its clinical oncology research, IOL is leveraging low-pass Whole Genome Sequencing (WGS) data computed by the proprietary GIInger deep-learning algorithm from SOPHiA GENETICS to increase research efficiency and obtain actionable clinical insights to make data-driven decisions that improve the quality of patient care.\n\n \n \n \n \n \n \n\n \nIOL will use SOPHiA DDM™ to identify Homologous Recombination Deficiency (HRD) in tumor samples. HRD is when a cell is unable to repair double-stranded breaks, which can lead to the accumulation of genomic scars. HRD is a common feature of high-grade serous ovarian cancer (HGSOC) as well as breast, prostate, and pancreatic cancers, and can be used as a potential predictive biomarker for therapy response.\n\"As the leading institution in the country for the detection, treatment and research of cancer, we work to ensure balanced and proper development of oncology health services. This is why research and education hold a special position at the Institute,\" said Dr. Srdjan Novaković, DSc (Biol.), Head of the Department of Molecular Diagnostic, Institute of Oncology Ljubljana. \"With the support of SOPHiA GENETICS, our researchers will be able to expedite testing and analysis associated with the determination of HRD, helping to facilitate faster clinical decision-making and advance cancer research in Slovenia.\"\nIOL will use the SOPHiA DDM™ Platform, which offers an application that is capable of combining information from germline and somatic homologous recombination repair (HRR) mutations, including BRCA1 and BRCA2, with a measure of genomic scarring. Through this approach, users can obtain reliable and fast, in-house data. HRR is a cellular process that repairs double-stranded breaks (DSB) arising from the DNA replication process or resulting from exposure to DNA-dam...